Healthpeak Properties
DOC
$16.42
+1.55%
Healthpeak Properties, Inc. is a real estate investment trust (REIT) that owns and operates a diversified portfolio of approximately 700 healthcare properties, primarily focused on medical office buildings and life science assets, with additional holdings in senior housing, hospitals, and skilled nursing facilities. The company is a prominent player in the healthcare REIT sector, leveraging its scale and specialized expertise in mission-critical healthcare real estate to generate stable cash flows from long-term tenants. The current investor narrative centers on the company's ability to navigate a challenging macroeconomic environment for real estate, characterized by higher interest rates, while demonstrating operational resilience through steady revenue growth and asset quality, as recent quarterly results show a return to positive net income after a volatile period.…
DOC
Healthpeak Properties
$16.42
Investment Opinion: Should I buy DOC Today?
Rating: Hold. The core thesis is that while the 7.59% dividend yield and oversold condition provide a margin of safety, the extreme valuation and earnings uncertainty create an unfavorable risk/reward profile, warranting a neutral stance pending clearer evidence of an earnings turnaround.
Supporting evidence includes a forward P/E of 121.7x, which is exceptionally high and demands flawless execution. Revenue growth is modest at 3.07% YoY in Q4 2025, indicating stable but not accelerating top-line expansion. The operating margin of 19.28% and robust TTM free cash flow of $1.17 billion are positive fundamentals. However, the stock trades at a 4.6% premium to its 52-week low, and the average analyst EPS target of $0.225 implies significant recovery is already priced in.
The thesis would upgrade to a Buy if the forward P/E compresses below 80x through sustained earnings growth or a further price decline, or if quarterly EPS consistently meets or exceeds the $0.225 estimate. It would downgrade to a Sell if revenue growth turns negative, the dividend yield becomes unsupported by free cash flow, or the stock breaks decisively below the $15.71 support level. Relative to its own history and REIT peers, the stock appears fairly valued on a Price-to-Book (1.49x) basis but is overvalued on an earnings basis, implying the market is paying a premium for an expected recovery that is far from certain.
Sign up to view all
DOC 12-Month Price Forecast
The outlook is balanced with a slight skew to the downside due to valuation risk. The base case of range-bound trading is most probable, as the high dividend provides a floor while the extreme P/E multiple caps near-term upside. The stock is a show-me story; investors need to see consecutive quarters of earnings meeting the elevated $0.225 annualized target to gain confidence. The stance would upgrade to bullish on evidence of sustained EPS delivery and multiple compression (e.g., forward P/E falling below 90x). It would turn bearish on a breakdown below $15.71 support or a cut to forward EPS estimates.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Healthpeak Properties's 12-month outlook, with a consensus price target around $21.35 and implied upside of +30.0% versus the current price.
Average Target
$21.35
2 analysts
Implied Upside
+30.0%
vs. current price
Analyst Count
2
covering this stock
Price Range
$13 - $21
Analyst target range
Analyst coverage for Healthpeak is limited, with only 4 analysts providing estimates, indicating it may be a less-followed mid-cap name within the REIT sector. The consensus sentiment appears mixed, with recent institutional ratings including one downgrade from 'Buy' to 'Hold' by Argus Research in early February 2026, balanced by maintained 'Outperform' ratings from Evercore ISI and Baird. The average revenue estimate for the next period is approximately $3.27 billion, with a wide range from $3.01 billion to $3.54 billion, reflecting significant uncertainty around the company's near-term financial performance. The average EPS estimate is $0.225, with a low of $0.202 and a high of $0.250, implying a forward P/E range of 73x to 90x based on the current price, which remains elevated and underscores the market's expectation for a substantial earnings recovery. The wide target ranges for both revenue and EPS signal high uncertainty and a lack of strong consensus on the company's near-term trajectory, which is typical for a stock navigating a volatile earnings period and a challenging interest rate environment for real estate.
Bulls vs Bears: DOC Investment Factors
The evidence currently tilts bearish, given the stock's severe underperformance, extreme valuation multiples predicated on a flawless earnings recovery, and persistent negative momentum. The bull case rests on the high dividend yield, strong free cash flow, and potential for a technical bounce from deeply oversold levels. The single most important tension in the investment debate is whether the company can deliver the substantial earnings rebound (to $0.225 EPS) that the lofty forward P/E of 121.7x implies. If achieved, the stock could re-rate higher; if missed, the current high multiple leaves immense room for downside.
Bullish
- Strong Free Cash Flow & Dividend Coverage: The company generates robust free cash flow of $1.17 billion TTM, which amply supports its attractive 7.59% dividend yield. This provides a tangible return to investors and signals underlying operational cash generation strength despite earnings volatility.
- Return to Profitability in Q4: Healthpeak reported a sharp rebound to net income of $114.0 million in Q4 2025, following a significant loss in Q3. This demonstrates operational resilience and suggests the company can navigate a challenging real estate environment to stabilize earnings.
- Stable Core Operating Margin: The operating margin of 19.28% indicates the core property business is generating substantial income before financing costs. This operational stability is a key strength for the REIT, supported by its portfolio of approximately 700 mission-critical healthcare properties.
- Analyst Expect Significant EPS Recovery: The forward EPS estimate of $0.225 implies a substantial recovery from the trailing EPS of $0.0064, lowering the forward P/E to 121.7x from 156.9x. This reflects analyst confidence in a near-term earnings rebound, which is a critical catalyst for the stock.
Bearish
- Extremely High Valuation Multiples: The stock trades at a trailing P/E of 156.9x and a forward P/E of 121.7x, which are astronomically high and signal the market is pricing in a perfect earnings recovery. Any stumble in the anticipated rebound would cause severe multiple compression.
- Severe Underperformance & Negative Momentum: DOC has underperformed the S&P 500 by 43.2% over the past year, with a -12.65% return versus the market's +30.59%. The stock is down 9.13% over the past three months, confirming persistent negative momentum and intense selling pressure.
- Volatile & Inefficient Earnings Profile: Profitability is highly inconsistent, with a net loss of -$117.1 million in Q3 2025 swinging to a profit in Q4. This volatility is reflected in weak return metrics, with an ROE of 0.95% and an ROA of 1.66%, indicating inefficient use of capital.
- High Leverage in Rising Rate Environment: A debt-to-equity ratio of 1.39 indicates moderate but meaningful leverage. In a macroeconomic environment characterized by higher interest rates, this increases refinancing risk and pressure on net income, a key headwind for real estate companies.
DOC Technical Analysis
The stock is in a pronounced downtrend, with a 1-year price change of -12.65%, significantly underperforming the S&P 500's 30.59% gain. Trading at a closing price of $16.43, the stock is positioned just 4.6% above its 52-week low of $15.71, indicating it is near the bottom of its annual range and may be in a deeply oversold condition or facing significant fundamental headwinds. The stock's beta of 1.08 suggests its volatility is only marginally higher than the broader market, yet its severe underperformance points to significant stock-specific or sector-specific pressures. Short-term momentum remains weak, with the stock down 2.26% over the past month and down 9.13% over the past three months, confirming the persistence of the longer-term bearish trend. This negative momentum has occurred despite a positive 8.7% return for the S&P 500 over the past month, resulting in a severe 1-month relative strength of -10.96%, highlighting intense selling pressure. The stock's price action over the last six months shows a consistent struggle to hold above the $18 level, with recent declines pushing it to test its 52-week low. Key technical support is clearly defined at the 52-week low of $15.71, while resistance lies near the 52-week high of $19.68. A decisive break below the $15.71 support could trigger a new leg down, whereas a recovery above the $18 level would be the first sign of a potential trend reversal, though the stock's high short interest ratio of 4.33 suggests a significant bearish bet by the market that could fuel a squeeze on any positive catalyst.
Beta
1.08
1.08x market volatility
Max Drawdown
-22.0%
Largest decline past year
52-Week Range
$16-$20
Price range past year
Annual Return
-7.6%
Cumulative gain past year
| Period | DOC Return | S&P 500 |
|---|---|---|
| 1m | +0.2% | +10.0% |
| 3m | -4.8% | +4.1% |
| 6m | -8.5% | +5.7% |
| 1y | -7.6% | +29.0% |
| ytd | +1.4% | +5.7% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
DOC Fundamental Analysis
Revenue growth has been modest but positive, with Q4 2025 revenue of $719.4 million representing a 3.07% year-over-year increase, though this follows a volatile pattern with a significant net loss in Q3 2025. The revenue segment data shows the Outpatient Medical Buildings segment contributed $626.5 million in the most recent period, indicating it is the dominant, stable driver of the top line. Profitability has been inconsistent; the company reported net income of $114.0 million in Q4 2025, a sharp rebound from a net loss of -$117.1 million in Q3 2025, while the trailing twelve-month net margin stands at a thin 2.53%. Gross margin was deeply negative at -87.2% in Q4 2025, but this is a GAAP accounting anomaly for REITs due to property depreciation; a more relevant metric is the operating margin of 19.28%, which indicates the core property operations are generating substantial income before financing and other costs. The balance sheet shows moderate leverage with a debt-to-equity ratio of 1.39, and the company maintains a healthy current ratio of 1.09. Free cash flow over the trailing twelve months is robust at $1.17 billion, providing ample coverage for the 7.59% dividend yield. However, return metrics are weak, with a Return on Equity (ROE) of just 0.95% and a Return on Assets (ROA) of 1.66%, signaling inefficient use of shareholder capital in the recent period.
Quarterly Revenue
$719402000.0B
2025-12
Revenue YoY Growth
+0.03%
YoY Comparison
Gross Margin
-0.87%
Latest Quarter
Free Cash Flow
$1.2B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is DOC Overvalued?
Given the company's positive but minimal trailing net income, we lead with the Price-to-Earnings (P/E) ratio, which stands at an extremely high 156.9x trailing and 121.7x forward. The forward P/E is lower than the trailing multiple, indicating analysts expect earnings to improve, with the forward EPS estimate of $0.225 representing a substantial increase from the trailing EPS of $0.0064. Compared to sector averages, the stock's Price-to-Sales (P/S) ratio of 3.97x and EV/EBITDA of 13.16x are more standard REIT valuation metrics, though the P/E is an outlier due to depressed earnings. The stock trades at a significant premium on a P/E basis, but this is largely a function of cyclical earnings weakness rather than an excessive growth premium. Historically, the stock's own valuation has compressed dramatically; the current P/E of 156.9x is astronomically higher than its historical range from recent quarters (e.g., 24.6x in Q4 2025, -28.5x in Q3 2025), but this is misleading as the denominator (EPS) has been near zero or negative. A more stable metric, the Price-to-Book ratio of 1.49x, is near the middle of its historical range over the past two years, suggesting the market is valuing the underlying assets at a moderate premium to accounting value, which is typical for healthcare REITs.
PE
156.9x
Latest Quarter
vs. Historical
Low-End
5-Year PE Range -28x~780x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
13.2x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks center on earnings volatility and leverage. The swing from a -$117.1 million net loss in Q3 2025 to a $114.0 million profit in Q4 highlights extreme earnings instability, making future income difficult to predict. A debt-to-equity ratio of 1.39, while not excessive, poses a refinancing risk in a higher interest rate environment, potentially pressuring margins. Furthermore, the extremely high P/E multiples (156.9x trailing) mean the stock is acutely vulnerable to any earnings disappointment, which could trigger severe multiple compression.
Market & Competitive Risks are pronounced. The stock trades at a significant premium on a P/E basis, though its Price-to-Book of 1.49x is more reasonable. The primary external threat is the sector-wide pressure from elevated interest rates, which compress real estate valuations and increase capital costs. The stock's beta of 1.08 suggests it is slightly more volatile than the market, yet its -43.2% relative strength over the past year indicates intense stock-specific selling pressure, likely driven by these macro concerns and earnings uncertainty.
Worst-Case Scenario involves a failure to achieve the anticipated earnings recovery, coupled with a deterioration in the commercial real estate market. If forward EPS estimates are cut and the sector faces further multiple compression, the stock could breach its key technical support at the 52-week low of $15.71. A realistic downside could see the stock fall to the $14-$15 range, representing a potential loss of 10-15% from the current price of $16.43. This scenario would be catalyzed by a Q2 or Q3 2026 earnings miss, leading to analyst downgrades and a loss of investor confidence in the dividend sustainability.
FAQ
The key risks are, in order of severity: 1) Valuation & Earnings Risk: The extreme P/E multiple leaves the stock vulnerable to a steep decline if the anticipated EPS recovery falters. 2) Macroeconomic Risk: As a REIT with a debt-to-equity of 1.39, it is sensitive to rising interest rates, which increase financing costs and pressure valuations. 3) Operational Risk: Earnings have been highly volatile, swinging from a $117M loss to a $114M profit in consecutive quarters, indicating underlying instability. 4) Sentiment & Technical Risk: The stock is in a strong downtrend, underperforming the S&P 500 by over 43% in a year, reflecting intense negative market sentiment.
The 12-month forecast presents three scenarios. The Base Case (55% probability) sees the stock trading between $16.50 and $18.00 as it makes uneven progress toward its $0.225 EPS target. The Bull Case (25% probability) projects a rally to $18.50-$19.70 on successful earnings delivery and a supportive rate environment. The Bear Case (20% probability) warns of a drop to $14.50-$15.71 if earnings miss and macro pressures intensify. The Base Case is most likely, hinging on the critical assumption that the company can achieve the full-year EPS of $0.225 that analysts expect.
DOC is overvalued on an earnings basis but may be fairly valued on an asset basis. The forward P/E of 121.7x is extremely high and indicates the market is pricing in a substantial and flawless earnings recovery. More standard REIT metrics like Price-to-Book (1.49x) and EV/EBITDA (13.16x) are within a more reasonable range. The valuation implies the market expects EPS to rebound sharply to $0.225; if this occurs, the stock could be fairly valued, but any shortfall would reveal it as significantly overvalued given the current price.
DOC presents a high-risk, high-potential-reward scenario. For income-seeking investors tolerant of volatility, the 7.59% dividend yield is attractive and appears well-covered by $1.17 billion in TTM free cash flow. However, the stock is not a good buy for growth or conservative investors, as it carries extreme valuation risk with a forward P/E of 121.7x and has severely underperformed the market. A purchase is only justified if you believe the company will hit its $0.225 EPS target and that the current price near its 52-week low adequately discounts the significant risks.
DOC is more suitable for a medium- to long-term investment horizon of 2-3 years, not short-term trading. The high dividend yield is a long-term return component, and the thesis depends on an earnings recovery that will take multiple quarters to confirm. The stock's beta of 1.08 and recent volatility make it a poor short-term trading vehicle. Investors should be prepared to hold through potential volatility to collect the dividend and allow time for the operational turnaround narrative to play out. A minimum holding period of 12-18 months is suggested to properly evaluate the investment thesis.